Thiazolidinediones - A new class of oral antidiabetics;Thiazolidinedioner - En ny klasse af orale antidiabetika

Ugeskrift for Laeger

Volumn 163, Issue 44, 2001, Pages 6106-6111

  Schmitz, O E ^a   Brock, B ^a   Madsbad, S ^a   Beck Nielsen, H ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALCOHOL; CELL NUCLEUS RECEPTOR; DIGOXIN; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RANITIDINE; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE; UNCLASSIFIED DRUG; WARFARIN; ANTIDIABETIC AGENT; CELL RECEPTOR; THIAZOLE DERIVATIVE;

CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG CROSS REACTIVITY; DRUG ELIMINATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEART DISEASE; HEART FUNCTION; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER TOXICITY; LONG TERM CARE; MEDICAL ASSESSMENT; MEDICAL LITERATURE; METABOLIC DISORDER; METABOLIC REGULATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; TREATMENT PLANNING; BLOOD; CHEMISTRY; DRUG EFFECT; GENETICS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES;

EID: 0035968733     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. "Insulin sensitisers" (glitazoner), fedme, insulinresistens - Er der en sammenhæng?
2. Roles of PPARs in health and disease
3. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists
4. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
5. Metabolic and vascular effects of the thiazolidinedione troglitazone
6. Insulin sensitiser drugs
7. Exercise and thiazolidinedione therapy normalize insulin action in the obese zucker fatty rat
8. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance
9. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats
10. Rosiglitazone
11. Pioglitazone
12. Rosiglitazone (BRL49653) monotherapy has significant glucose lowering effect in type 2 diabetic patients
13. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes
14. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus
15. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial
16. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients
17. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study
18. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
19. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM
20. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients
21. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled study
22. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial
23. Troglitazone in combination with sulphonylurea improves glycaemic control in type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone
24. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes
25. Cardiac and glycemic benefits of troglitazone treatment in NIDDM
26. Effect of troglitazone on body fat distribution in type 2 diabetic patients
27. Long-term efficacy of rosiglitazone as monotherapy or in combination with metformin
28. Rosiglitazone (RSG) is safe and well tolerated as monotherapy or combination therapy with type 2 diabetes mellitus (T2DM)
29. Hepatic failure in a patient taking rosiglitazone
30. Hepatocellular injury in a patient receiving rosiglitazone. A case report
31. Isolated elevation of alkaline phosphatase level associated with rosiglitazone
32. Rosiglitazone Toxicity
33. Rosiglitazone (RSG) improves glycemic control in poorly controlled, insulin-treated type 2 diabetes (T2D)
34. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
35. Adverse effects with pioglitazone HCL
36. Rosiglitazone: No effect on erythropoiesis or premature red cell destruction
37. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism
38. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy
39. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives